Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...
New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.
Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable hepatocellular carcinoma. The recommended single-agent dose is 400 mg orally twice a day ...
Announcing a new publication for Acta Materia Medica journal. Epithelial cell adhesion molecule (EpCAM) is a biomarker for epithelial cell-derived tumors. However, the specific role of EpCAM itself in ...
Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...
Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...
Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback